NetworkNewsBreaks – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) Receives ‘Buy’ Rating, $12 PT

Aegis Capital recently issued a ‘Buy’ rating and price target of $12 on shares of Corbus Pharmaceuticals Holdings (NASDAQ: CRBP). The company’s fourth quarter was marked by positive data from its phase 2 study of anabasum (previously Resunab or JBT-101) for the treatment of systemic sclerosis showing clear signal of clinical benefit. On March 13, Corbus held a Research and Development day and said the anticipated data from the phase 2a study in cystic fibrosis is on schedule for announcement during March 2017. Aegis cited this data as a possible milestone to drive shares of the company’s stock.

For more information, visit

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company’s lead product candidate, JBT-101, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, and fibrotic processes. In November 2016, Corbus reported positive topline data results from a phase 2 study in diffuse cutaneous systemic sclerosis, showing clear signal of clinical benefit with JBT-101. The company recently completed a phase 2 study of JBT-101 for the treatment of cystic fibrosis with topline data expected to be announced by the end of the first quarter of 2017. Additionally, JBT-101 is being evaluated in a phase 2, 12-month open-label extension study in systemic sclerosis, a phase 2 study in skin-predominant dermatomyositis, with a 12-month open-label extension study in dermatomyositis and another phase 2 study in systemic lupus erythematosus planned to commence in the second quarter of 2017.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s